$IRWD
IRONWOOD PHARMACEUTICALS INC

2023 Q1 Form 10-K Financial Statement

#000155837023001462 Filed on February 16, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $104.1M $107.2M $410.6M
YoY Change 6.7% -8.48% -0.76%
Cost Of Revenue $0.00
YoY Change
Gross Profit $410.6M
YoY Change -0.76%
Gross Profit Margin 100.0%
Selling, General & Admin $31.12M $28.39M $116.0M
YoY Change 7.82% -1.03% 4.37%
% of Gross Profit 28.25%
Research & Development $12.85M $10.45M $44.27M
YoY Change 18.71% -67.2% -37.13%
% of Gross Profit 10.78%
Depreciation & Amortization $286.0K $340.0K $1.400M
YoY Change -19.44% -5.29% -6.67%
% of Gross Profit 0.34%
Operating Expenses $43.96M $38.84M $160.3M
YoY Change 10.79% -35.85% -11.72%
Operating Profit $60.10M $250.3M
YoY Change 3.89% 7.78%
Interest Expense $1.527M $3.902M $7.598M
YoY Change -34.77% -137.75% -75.61%
% of Operating Profit 2.54% 3.04%
Other Income/Expense, Net $5.764M $3.902M $2.085M
YoY Change -517.38% -137.75% -106.6%
Pretax Income $65.86M $72.27M $252.4M
YoY Change 16.64% 56.23% 25.8%
Income Tax $20.10M $23.40M $77.36M
% Of Pretax Income 30.52% 32.38% 30.65%
Net Earnings $45.71M $48.87M $175.1M
YoY Change 17.82% 18.11% -66.87%
Net Earnings / Revenue 43.93% 45.59% 42.64%
Basic Earnings Per Share $0.30 $0.32 $1.13
Diluted Earnings Per Share $0.25 $0.27 $0.96
COMMON SHARES
Basic Shares Outstanding 154.2M 153.4M 154.4M
Diluted Shares Outstanding 186.7M 186.3M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $740.3M $656.2M $656.2M
YoY Change 24.77% 5.82% 5.82%
Cash & Equivalents $740.3M $656.2M $656.2M
Short-Term Investments
Other Short-Term Assets $10.28M $8.965M $8.965M
YoY Change -8.31% -18.9% -18.9%
Inventory
Prepaid Expenses
Receivables $115.7M $115.5M $115.5M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $866.4M $780.6M $780.6M
YoY Change 22.01% 4.75% 4.75%
LONG-TERM ASSETS
Property, Plant & Equipment $6.015M $6.288M $20.31M
YoY Change -16.79% -16.99% -11.4%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $820.0K $847.0K $285.0M
YoY Change -14.14% -15.3% -14.87%
Total Long-Term Assets $288.9M $319.9M $319.9M
YoY Change -22.6% -16.19% -16.19%
TOTAL ASSETS
Total Short-Term Assets $866.4M $780.6M $780.6M
Total Long-Term Assets $288.9M $319.9M $319.9M
Total Assets $1.155B $1.101B $1.101B
YoY Change 6.64% -2.34% -2.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $118.0K $483.0K $483.0K
YoY Change -77.82% -48.34% -48.34%
Accrued Expenses $23.73M $25.02M $25.02M
YoY Change -6.56% -41.25% -41.25%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $23.84M $25.53M $25.53M
YoY Change -83.82% -84.21% -84.21%
LONG-TERM LIABILITIES
Long-Term Debt $396.7M $396.3M $396.3M
YoY Change 0.41% 17.47% 17.47%
Other Long-Term Liabilities $11.82M $9.766M $26.37M
YoY Change 131.34% 178.95% 19.92%
Total Long-Term Liabilities $11.82M $9.766M $422.6M
YoY Change 131.34% 178.95% 17.62%
TOTAL LIABILITIES
Total Short-Term Liabilities $23.84M $25.53M $25.53M
Total Long-Term Liabilities $11.82M $9.766M $422.6M
Total Liabilities $35.67M $35.29M $448.1M
YoY Change -76.61% -78.64% -13.99%
SHAREHOLDERS EQUITY
Retained Earnings -$650.7M -$696.4M
YoY Change -21.86% -25.73%
Common Stock $1.358B $1.349B
YoY Change 0.53% -12.62%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $706.9M $652.4M $652.4M
YoY Change
Total Liabilities & Shareholders Equity $1.155B $1.101B $1.101B
YoY Change 6.64% -2.34% -2.34%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income $45.71M $48.87M $175.1M
YoY Change 17.82% 18.11% -66.87%
Depreciation, Depletion And Amortization $286.0K $340.0K $1.400M
YoY Change -19.44% -5.29% -6.67%
Cash From Operating Activities $80.17M $79.18M $273.8M
YoY Change 25.02% 22.63% 4.53%
INVESTING ACTIVITIES
Capital Expenditures $13.00K -$27.00K $136.0K
YoY Change 44.44% -78.91% -48.68%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$13.00K $27.00K -$136.0K
YoY Change 44.44% -121.09% -48.68%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $126.4M
YoY Change 423.78%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.981M 2.806M -237.6M
YoY Change -104.38% -115.1% 5120.95%
NET CHANGE
Cash From Operating Activities 80.17M 79.18M 273.8M
Cash From Investing Activities -13.00K 27.00K -136.0K
Cash From Financing Activities 3.981M 2.806M -237.6M
Net Change In Cash 84.14M 82.02M 36.07M
YoY Change -414.44% 78.87% -85.97%
FREE CASH FLOW
Cash From Operating Activities $80.17M $79.18M $273.8M
Capital Expenditures $13.00K -$27.00K $136.0K
Free Cash Flow $80.16M $79.21M $273.6M
YoY Change 25.02% 22.43% 4.59%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Accounts Receivable Net Noncurrent
AccountsReceivableNetNoncurrent
23998000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6288000
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 us-gaap Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List
FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
http://fasb.org/us-gaap/2022#GainLossOnDerivativeInstrumentsNetPretax
CY2022 us-gaap Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List
FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
http://fasb.org/us-gaap/2022#GainLossOnDerivativeInstrumentsNetPretax
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001446847
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
620129000
CY2022Q4 us-gaap Derivative Liability Statement Of Financial Position Extensible Enumeration
DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
http://fasb.org/us-gaap/2022#HedgingLiabilitiesCurrent
CY2021Q4 us-gaap Derivative Asset Statement Of Financial Position Extensible Enumeration
DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration
http://fasb.org/us-gaap/2022#HedgingAssetsCurrent
CY2021Q4 us-gaap Derivative Liability Statement Of Financial Position Extensible Enumeration
DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
http://fasb.org/us-gaap/2022#HedgingLiabilitiesCurrent
CY2022Q4 us-gaap Derivative Liability Valuation Technique Extensible List
DerivativeLiabilityValuationTechniqueExtensibleList
http://fasb.org/us-gaap/2022#ValuationTechniqueOptionPricingModelMember
CY2021Q4 us-gaap Derivative Asset Valuation Technique Extensible List
DerivativeAssetValuationTechniqueExtensibleList
http://fasb.org/us-gaap/2022#ValuationTechniqueOptionPricingModelMember
CY2021Q4 us-gaap Derivative Liability Valuation Technique Extensible List
DerivativeLiabilityValuationTechniqueExtensibleList
http://fasb.org/us-gaap/2022#ValuationTechniqueOptionPricingModelMember
CY2021 us-gaap Fair Value Recurring Basis Unobservable Input Reconciliation Asset Gain Loss Statement Of Income Extensible List
FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList
http://fasb.org/us-gaap/2022#GainLossOnDerivativeInstrumentsNetPretax
CY2022 us-gaap Fair Value Recurring Basis Unobservable Input Reconciliation Asset Gain Loss Statement Of Income Extensible List
FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList
http://fasb.org/us-gaap/2022#GainLossOnDerivativeInstrumentsNetPretax
CY2020 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-34620
CY2022 dei Entity Registrant Name
EntityRegistrantName
IRONWOOD PHARMACEUTICALS, INC.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-3404176
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
100 Summer Street
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 2300
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02110
CY2022 dei City Area Code
CityAreaCode
617
CY2022 dei Local Phone Number
LocalPhoneNumber
621-7722
CY2022 dei Security12b Title
Security12bTitle
Class A Common Stock, $0.001 par value
CY2022 dei Entity Listing Par Value Per Share
EntityListingParValuePerShare
0.001
CY2022 dei Trading Symbol
TradingSymbol
IRWD
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
false
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
1555346291
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
154158046
CY2022 dei Auditor Firm
AuditorFirmId
42
CY2022 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2022 dei Auditor Location
AuditorLocation
Boston, Massachusetts
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
656203000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
115458000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
114042000
CY2021Q4 us-gaap Hedging Assets Current
HedgingAssetsCurrent
1115000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
780626000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
745225000
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
1250000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7715000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
485000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8689000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
1250000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
485000
CY2022Q4 us-gaap Accounts Receivable Net Noncurrent
AccountsReceivableNetNoncurrent
14589000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7575000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
14023000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
15350000
CY2022Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
283661000
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
333294000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
847000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1000000
CY2022Q4 us-gaap Assets
Assets
1100519000
CY2021Q4 us-gaap Assets
Assets
1126927000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
483000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
935000
CY2022Q4 irwd Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
5258000
CY2021Q4 irwd Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
15896000
CY2022Q4 irwd Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
16700000
CY2021Q4 irwd Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
23566000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3065000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3127000
CY2021Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
116858000
CY2022Q4 us-gaap Hedging Liabilities Current
HedgingLiabilitiesCurrent
19000
CY2021Q4 us-gaap Hedging Liabilities Current
HedgingLiabilitiesCurrent
1316000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
25525000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
161698000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
16599000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
18484000
CY2022Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
396251000
CY2021Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
337333000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
9766000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3501000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
75000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
75000000
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
154026949
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
154026949
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
162036461
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
162036461
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
154000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
162000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1348600000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1543357000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-696376000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-937608000
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-7523000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
652378000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1100519000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1126927000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
605911000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
410596000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
389523000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
413753000
CY2020 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3136000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44265000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
70405000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
88062000
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
115994000
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
111133000
CY2020 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
140003000
CY2021 irwd Restructuring Expense Benefit
RestructuringExpenseBenefit
-44000
CY2020 irwd Restructuring Expense Benefit
RestructuringExpenseBenefit
15382000
CY2022 us-gaap Costs And Expenses
CostsAndExpenses
160259000
CY2021 us-gaap Costs And Expenses
CostsAndExpenses
181494000
CY2020 us-gaap Costs And Expenses
CostsAndExpenses
246583000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
250337000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
232259000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
142940000
CY2022 us-gaap Interest Expense
InterestExpense
7598000
CY2021 us-gaap Interest Expense
InterestExpense
31150000
CY2020 us-gaap Interest Expense
InterestExpense
29478000
CY2022 us-gaap Investment Income Net
InvestmentIncomeNet
9501000
CY2021 us-gaap Investment Income Net
InvestmentIncomeNet
726000
CY2020 us-gaap Investment Income Net
InvestmentIncomeNet
1504000
CY2022 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
182000
CY2021 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-1178000
CY2020 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-6129000
CY2020 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
24000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2085000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-31602000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-34079000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
252422000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
200657000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
108861000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
77357000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-327791000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2685000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
175065000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
175065000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
528448000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
528448000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
106176000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
106176000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.13
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.26
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.67
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.96
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.21
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.66
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
154366000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
162245000
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
159427000
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
186312000
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
164418000
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
160655000
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-93251000
CY2020 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
18540000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
31175000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
106176000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
62640000
CY2021 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
19681000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
22281000
CY2021 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
27139000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
528448000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
605911000
CY2022 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
11790000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
27048000
CY2022 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
123386000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
175065000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
652378000
CY2022 us-gaap Profit Loss
ProfitLoss
175065000
CY2021 us-gaap Profit Loss
ProfitLoss
528448000
CY2020 us-gaap Profit Loss
ProfitLoss
106176000
CY2022 us-gaap Depreciation
Depreciation
1418000
CY2021 us-gaap Depreciation
Depreciation
1523000
CY2020 us-gaap Depreciation
Depreciation
3564000
CY2022 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-2000
CY2021 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-93000
CY2020 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-470000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
27048000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
22281000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
31175000
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1297000
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-10772000
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-12172000
CY2022 irwd Fair Value Adjustment Of Convertible Note Hedging Instrument
FairValueAdjustmentOfConvertibleNoteHedgingInstrument
1115000
CY2021 irwd Fair Value Adjustment Of Convertible Note Hedging Instrument
FairValueAdjustmentOfConvertibleNoteHedgingInstrument
11950000
CY2020 irwd Fair Value Adjustment Of Convertible Note Hedging Instrument
FairValueAdjustmentOfConvertibleNoteHedgingInstrument
18301000
CY2022 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1853000
CY2021 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
23935000
CY2020 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
22263000
CY2022 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
65739000
CY2021 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-333294000
CY2022 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-7993000
CY2021 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-7712000
CY2020 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-4091000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3224000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-601000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1515000
CY2021 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
3452000
CY2021 irwd Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-1226000
CY2020 irwd Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-1167000
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-8116000
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2644000
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-648000
CY2022 irwd Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-1327000
CY2022 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-153000
CY2021 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
57000
CY2020 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
153000
CY2020 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1848000
CY2021 irwd Stock Repurchases Payable In Accrued Expenses
StockRepurchasesPayableInAccruedExpenses
3009000
CY2022 irwd Stock Option Exercise Proceeds Receivable In Other Current Assets
StockOptionExerciseProceedsReceivableInOtherCurrentAssets
2351000
CY2021 irwd Stock Option Exercise Proceeds Receivable In Other Current Assets
StockOptionExerciseProceedsReceivableInOtherCurrentAssets
101000
CY2022 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">1. Nature of Business </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Ironwood Pharmaceuticals, Inc. (the “Company”) is a gastrointestinal (“GI”) healthcare company dedicated to advancing the treatment of GI diseases and redefining the standard of care for GI patients. The Company is focused on the development and commercialization of innovative GI product opportunities in areas of significant unmet need, leveraging its demonstrated expertise and capabilities in GI diseases. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">LINZESS<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup><span style="white-space:pre-wrap;"> (linaclotide), the Company’s commercial product, is the first product approved by the United States Food and Drug Administration (the “U.S. FDA”) in a class of GI medicines called guanylate cyclase type C agonists (“GC-C agonists”) and is indicated for adult men and women suffering from irritable bowel syndrome with constipation (“IBS-C”) or chronic idiopathic constipation (“CIC”). LINZESS is available to adult men and women suffering from IBS-C or CIC in the United States (the “U.S.”) and Mexico and to adult men and women suffering from IBS-C in Japan and China. Linaclotide is available under the trademarked name CONSTELLA</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> to adult men and women suffering from IBS-C or CIC in Canada, and to adult men and women suffering from IBS-C in certain European countries. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company has strategic partnerships with leading pharmaceutical companies to support the development and commercialization of linaclotide throughout the world. The Company and its partner, AbbVie Inc. (together with its affiliates, “AbbVie”), began commercializing LINZESS in the U.S. in December 2012. Under the Company’s collaboration for North America with AbbVie, total net sales of LINZESS in the U.S., as recorded by AbbVie, are reduced by commercial costs incurred by each party, and the resulting amount is shared equally between the Company and AbbVie. Additionally, development costs are shared equally between the Company and AbbVie. The Company and AbbVie are exploring ways to enhance the clinical profile of LINZESS by studying linaclotide in additional indications, populations and formulations to assess its potential to treat various conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Outside of the U.S., the Company earns royalties as a percentage of net sales of products containing linaclotide as an active ingredient by the Company’s collaboration partners. AbbVie has an exclusive license from the Company to develop and commercialize linaclotide in all countries other than China (including Hong Kong and Macau), Japan and the countries and territories of North America (“the AbbVie License Territory”). In addition, AbbVie has exclusive rights to commercialize linaclotide in Canada as CONSTELLA and in Mexico as LINZESS. Astellas Pharma Inc. (“Astellas”), the Company’s partner in Japan, has an exclusive license to develop, manufacture, and commercialize linaclotide in Japan. AstraZeneca AB (together with its affiliates) (“AstraZeneca”), the Company’s partner in China, has the exclusive right to develop, manufacture, and commercialize products containing linaclotide in China (including Hong Kong and Macau) (the “AstraZeneca License Territory”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company has a collaboration and license option agreement (the “COUR Collaboration Agreement”) with COUR Pharmaceutical Development Company, Inc. (“COUR”), a biotechnology company developing novel immune-modifying nanoparticles to treat autoimmune diseases. The COUR Collaboration Agreement grants the Company an option to acquire an exclusive license to research, develop, manufacture and commercialize, in the U.S., products containing CNP-104, a potential treatment for primary biliary cholangitis, a rare autoimmune disease targeting the liver.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">These and other agreements are more fully described in Note 4, <i style="font-style:italic;">Collaboration, License, and Other Agreements,</i> to these consolidated financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company is also advancing IW-3300, a GC-C agonist, for the potential treatment of visceral pain conditions, including interstitial cystitis / bladder pain syndrome (“IC/BPS”) and endometriosis. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company was incorporated in Delaware on January 5, 1998 as Microbia, Inc. On April 7, 2008, the Company changed its name to Ironwood Pharmaceuticals, Inc. To date, the Company has dedicated a majority of its activities to the research, development and commercialization of linaclotide, as well as to the research and development of its other product candidates. </p>
CY2022 irwd Increase Decrease In Accrued Research And Development Expense
IncreaseDecreaseInAccruedResearchAndDevelopmentExpense
-10638000
CY2021 irwd Increase Decrease In Accrued Research And Development Expense
IncreaseDecreaseInAccruedResearchAndDevelopmentExpense
13998000
CY2020 irwd Increase Decrease In Accrued Research And Development Expense
IncreaseDecreaseInAccruedResearchAndDevelopmentExpense
-1058000
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1947000
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1835000
CY2020 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
218000
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-875000
CY2022 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
10824000
CY2021 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-1270000
CY2020 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
1029000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
273763000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
261895000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
168836000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
136000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
265000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1842000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-136000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-265000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1842000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
9540000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
19581000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
18546000
CY2022 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
120699000
CY2022 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
126394000
CY2021 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
24131000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-237553000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-4550000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18546000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
36074000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
257080000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
185540000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
621864000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
364784000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
179244000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
657938000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
621864000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
364784000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
656203000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
620129000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
362564000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
1735000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
1735000
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
2220000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
657938000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
621864000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
364784000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
5745000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
7216000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
7216000
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
4615000
CY2020 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2021 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2022 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2022 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Reclassifications</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"/>Certain prior period financial statement items have been reclassified to conform to current period presentation.</p>
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in accordance with U.S. generally accepted accounting principles requires the Company’s management to make estimates and judgments that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the amounts of revenues and expenses during the reported periods. On an ongoing basis, the Company’s management evaluates its estimates, judgments and methodologies. Significant estimates and assumptions in the consolidated financial statements include those related to revenue recognition; accounts receivable; useful lives of long-lived assets, impairment of long-lived assets, including goodwill; valuation procedures for right-of-use assets and operating lease liabilities; valuation procedures for the issuance and repurchase of convertible notes; balance sheet classification of convertible notes; fair value of derivatives; income taxes, including the valuation allowance for deferred tax assets; research and development expenses; contingencies and share-based compensation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ materially from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.</p>
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
650200000
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
595200000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
1700000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
1700000
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
1300000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
1300000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
500000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
500000
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Concentrations of Credit Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents, restricted cash, and accounts receivable. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and the Company believes that such funds are subject to minimal credit risk. The Company has adopted an investment policy which limits the amounts the Company may invest in certain types of investments, and requires all investments held by the Company to be at least A- rated, thereby reducing credit risk exposure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accounts receivable primarily consist of amounts due under the linaclotide collaboration agreement with AbbVie for North America (Note 4). The Company does not obtain collateral for its accounts receivable. The Company previously reflected amounts due from Allergan plc (“Allergan”), net of amounts payable to Allergan, prior to its acquisition by AbbVie as related party accounts receivable, net. Following the acquisition of Allergan by AbbVie, the Company determined that AbbVie is not a related party to the Company (Note 15).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The percentages of revenue recognized from significant collaborative partners of the Company in the years ended December 31, 2022, 2021 and 2020 as well as the account receivable balances, net of any payables due, at December 31, 2022 and 2021 are included in the following table: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accounts</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Receivable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:61.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:61.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:61.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Collaborative Partner:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">AbbVie (North America and Europe)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p>
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1316000
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
-1115000
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
1297000
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
0
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
19000
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
333294000
CY2021Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
116858000
CY2021Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
337333000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1543357000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-937608000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
175065000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
528448000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
106176000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
179514000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
528448000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
106176000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
154366000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
162245000
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
159427000
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
186312000
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
164418000
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
160655000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.13
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.26
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.67
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.96
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.21
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.66
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
2509000
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15662000
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
54428000
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
58554000
CY2022Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
130000000.0
CY2021Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
138000000.0
CY2022Q4 irwd Accounts Receivable Net Of Accounts Payable Current And Noncurrent
AccountsReceivableNetOfAccountsPayableCurrentAndNoncurrent
104400000
CY2021Q4 irwd Accounts Receivable Net Of Accounts Payable Current And Noncurrent
AccountsReceivableNetOfAccountsPayableCurrentAndNoncurrent
112200000
CY2022 irwd Milestone Payment To Be Received By Company Upon Milestone Achievement
MilestonePaymentToBeReceivedByCompanyUponMilestoneAchievement
90000000.0
CY2022Q4 irwd Threshold Percentage Of Collateralized Value
ThresholdPercentageOfCollateralizedValue
1.02
CY2022Q4 irwd Threshold Percentage Of Collateralized Value
ThresholdPercentageOfCollateralizedValue
1.02
CY2020Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
13065000
CY2020Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
12088000
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
-11950000
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
10772000
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
1115000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
2520000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
1700000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
1700000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10764000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9628000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6288000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7575000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
2530000
CY2022 us-gaap Short Term Lease Cost
ShortTermLeaseCost
1070000
CY2021 us-gaap Short Term Lease Cost
ShortTermLeaseCost
960000
CY2020 us-gaap Short Term Lease Cost
ShortTermLeaseCost
1420000
CY2022 us-gaap Lease Cost
LeaseCost
3579000
CY2021 us-gaap Lease Cost
LeaseCost
3480000
CY2020 us-gaap Lease Cost
LeaseCost
3950000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
3114000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
3128000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
1146000
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y3M18D
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y3M18D
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y3M18D
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.058
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.058
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.058
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3066000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3126000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3189000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
3252000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
3317000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
8285000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
24235000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4571000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
19664000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3065000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
16599000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
17052000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
17203000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1400000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1500000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2300000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
12268000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
16653000
CY2021Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
462000
CY2021Q4 irwd Accrued Stock Repurchase Liability Current
AccruedStockRepurchaseLiabilityCurrent
3009000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4432000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3442000
CY2022Q4 irwd Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
16700000
CY2021Q4 irwd Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
23566000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4400000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3400000
CY2022Q4 irwd Other Accrued Liabilities Current Uninvoiced Vendor Liabilities
OtherAccruedLiabilitiesCurrentUninvoicedVendorLiabilities
3600000
CY2021Q4 irwd Other Accrued Liabilities Current Uninvoiced Vendor Liabilities
OtherAccruedLiabilitiesCurrentUninvoicedVendorLiabilities
2700000
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
-290000
CY2022 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
5745000
CY2021 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
7216000
CY2020 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
7216000
CY2022 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1853000
CY2021 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1678000
CY2020 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1462000
CY2021 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
22256000
CY2020 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
20800000
CY2022 us-gaap Interest Expense Debt
InterestExpenseDebt
7598000
CY2021 us-gaap Interest Expense Debt
InterestExpenseDebt
31150000
CY2020 us-gaap Interest Expense Debt
InterestExpenseDebt
29478000
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
4500000
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
203750000
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
3000000
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
201500000
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
412750000
CY2022Q4 irwd Long Term Debt Maturities Interest Payments
LongTermDebtMaturitiesInterestPayments
12750000
CY2022Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
3749000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
396251000
CY2015Q2 us-gaap Payments Of Derivative Issuance Costs
PaymentsOfDerivativeIssuanceCosts
21100000
CY2019Q3 irwd Proceeds From Partial Termination Of Convertible Note Hedges And Warrants
ProceedsFromPartialTerminationOfConvertibleNoteHedgesAndWarrants
3200000
CY2022 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Class A Common Stock is entitled to one vote per share.
CY2022Q4 irwd Common Stock Voting Rights Per Share
CommonStockVotingRightsPerShare
1
CY2021Q2 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
150000000.0
CY2022 us-gaap Stock Repurchased And Retired During Period Shares
StockRepurchasedAndRetiredDuringPeriodShares
10800000
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
426000
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
325000
CY2022 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
123400000
us-gaap Stock Repurchased And Retired During Period Shares
StockRepurchasedAndRetiredDuringPeriodShares
13100000
irwd Stock Repurchased And Retired During Period Weighted Average Price
StockRepurchasedAndRetiredDuringPeriodWeightedAveragePrice
11.47
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
27048000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22281000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
31175000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
27048000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22281000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
31175000
CY2022 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
1644000
CY2022 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
28692000
CY2021 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
22281000
CY2020 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
31175000
CY2022 irwd Share Based Compensation Arrangements By Share Based Payment Award Options Expiration Term
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm
P10Y
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.89
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9372794
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.30
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y6M3D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4528000
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
951355
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
10.88
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
1490067
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
13.04
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6931372
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.34
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y3M25D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
5786000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
6929248
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
12.34
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P3Y3M25D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
5782000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
6877104
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
12.35
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y3M18D
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
5709000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
900000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2700000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3500000
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
11618000
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
5503000
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
2685000
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
11618000
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
5503000
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
2685000
CY2022 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
52191000
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-251367000
CY2022 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
13548000
CY2021 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-81927000
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
65739000
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-333294000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
77357000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-327791000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2685000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
77400000
CY2022 irwd Income Tax Expense Benefit Non Cash
IncomeTaxExpenseBenefitNonCash
73400000
CY2022 irwd Income Tax Expense Benefit Cash
IncomeTaxExpenseBenefitCash
4000000.0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-327800000
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
5500000
CY2020 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
2700000
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
53009000
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
42138000
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
22861000
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
16160000
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
12554000
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
7565000
CY2022 irwd Effective Income Tax Rate Reconciliation Executive Compensation
EffectiveIncomeTaxRateReconciliationExecutiveCompensation
2654000
CY2021 irwd Effective Income Tax Rate Reconciliation Executive Compensation
EffectiveIncomeTaxRateReconciliationExecutiveCompensation
695000
CY2020 irwd Effective Income Tax Rate Reconciliation Executive Compensation
EffectiveIncomeTaxRateReconciliationExecutiveCompensation
1718000
CY2022 irwd Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost Windfalls
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCostWindfalls
-3613000
CY2021 irwd Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost Windfalls
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCostWindfalls
-6270000
CY2020 irwd Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost Windfalls
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCostWindfalls
-5132000
CY2022 irwd Income Tax Reconciliation Fair Market Valuation Of Note Hedge Warrants And Convertible Note Hedges
IncomeTaxReconciliationFairMarketValuationOfNoteHedgeWarrantsAndConvertibleNoteHedges
-50000
CY2021 irwd Income Tax Reconciliation Fair Market Valuation Of Note Hedge Warrants And Convertible Note Hedges
IncomeTaxReconciliationFairMarketValuationOfNoteHedgeWarrantsAndConvertibleNoteHedges
325000
CY2020 irwd Income Tax Reconciliation Fair Market Valuation Of Note Hedge Warrants And Convertible Note Hedges
IncomeTaxReconciliationFairMarketValuationOfNoteHedgeWarrantsAndConvertibleNoteHedges
1680000
CY2022 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
252000
CY2021 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
9000
CY2020 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
3149000
CY2022 irwd Income Tax Reconciliation Expiring Net Operating Losses And Tax Credits
IncomeTaxReconciliationExpiringNetOperatingLossesAndTaxCredits
1087000
CY2021 irwd Income Tax Reconciliation Expiring Net Operating Losses And Tax Credits
IncomeTaxReconciliationExpiringNetOperatingLossesAndTaxCredits
491000
CY2020 irwd Income Tax Reconciliation Expiring Net Operating Losses And Tax Credits
IncomeTaxReconciliationExpiringNetOperatingLossesAndTaxCredits
1991000
CY2022 irwd Income Tax Reconciliation Change In Enacted State And Local Tax Rates
IncomeTaxReconciliationChangeInEnactedStateAndLocalTaxRates
2581000
CY2021 irwd Income Tax Reconciliation Change In Enacted State And Local Tax Rates
IncomeTaxReconciliationChangeInEnactedStateAndLocalTaxRates
123000
CY2020 irwd Income Tax Reconciliation Change In Enacted State And Local Tax Rates
IncomeTaxReconciliationChangeInEnactedStateAndLocalTaxRates
-208000
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-1155000
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-390804000
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-35230000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
77357000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-327791000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2685000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
88769000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
165022000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
59290000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
60125000
CY2022Q4 irwd Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
12683000
CY2021Q4 irwd Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
4981000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
13666000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
16857000
CY2022Q4 irwd Deferred Tax Assets Collaboration Agreement
DeferredTaxAssetsCollaborationAgreement
95460000
CY2021Q4 irwd Deferred Tax Assets Collaboration Agreement
DeferredTaxAssetsCollaborationAgreement
78194000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
5935000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
5003000
CY2022Q4 irwd Deferred Tax Assets Basis Difference On Convertible Notes
DeferredTaxAssetsBasisDifferenceOnConvertibleNotes
2845000
CY2021Q4 irwd Deferred Tax Assets Basis Difference On Convertible Notes
DeferredTaxAssetsBasisDifferenceOnConvertibleNotes
8166000
CY2022Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
5299000
CY2021Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
5396000
CY2022Q4 irwd Deferred Tax Assets Operating Leases
DeferredTaxAssetsOperatingLeases
5337000
CY2021Q4 irwd Deferred Tax Assets Operating Leases
DeferredTaxAssetsOperatingLeases
5971000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1242000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
3997000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
290526000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
353712000
CY2021Q4 irwd Deferred Tax Liabilities Basis Difference Convertible Notes
DeferredTaxLiabilitiesBasisDifferenceConvertibleNotes
11960000
CY2022Q4 irwd Deferred Tax Liabilities Operating Lease Right Of Use Assets
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
3810000
CY2021Q4 irwd Deferred Tax Liabilities Operating Lease Right Of Use Assets
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
4248000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
3810000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
16208000
CY2020 irwd Defined Contribution Plan Employer Matching Contribution Employee Contribution Percent
DefinedContributionPlanEmployerMatchingContributionEmployeeContributionPercent
0.75
CY2020 irwd Defined Contribution Plan Employer Matching Contribution Employee Contribution Maximum
DefinedContributionPlanEmployerMatchingContributionEmployeeContributionMaximum
6000
CY2022 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
2200000
CY2021 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
2200000
CY2022Q4 irwd Deferred Tax Assets Net Including Valuation Allowances
DeferredTaxAssetsNetIncludingValuationAllowances
286716000
CY2021Q4 irwd Deferred Tax Assets Net Including Valuation Allowances
DeferredTaxAssetsNetIncludingValuationAllowances
337504000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
3055000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
4210000
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
283661000
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
333294000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
3100000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-1200000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-390800000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-35200000
CY2022Q4 us-gaap Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
63900000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
84606000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
68087000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
53099000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
101225000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
83206000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
66687000
CY2022 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
83206000
CY2021 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
66687000
CY2020 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
51699000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
102625000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
84606000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
68087000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
102600000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
84600000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
68100000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
102600000
CY2022Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
1400000
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
9200000
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
2900000
CY2020 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1800000
CY2020Q4 us-gaap Restructuring Reserve
RestructuringReserve
10907000
CY2021 us-gaap Restructuring Charges
RestructuringCharges
1073000
CY2021 us-gaap Payments For Restructuring
PaymentsForRestructuring
10664000
CY2021 us-gaap Restructuring Reserve Accrual Adjustment1
RestructuringReserveAccrualAdjustment1
-854000
CY2021Q4 us-gaap Restructuring Reserve
RestructuringReserve
462000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
97529000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
97231000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
108637000
CY2022Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
107199000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
410596000
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
39683000
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
41576000
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
40164000
CY2022Q4 us-gaap Costs And Expenses
CostsAndExpenses
38836000
CY2022 us-gaap Costs And Expenses
CostsAndExpenses
160259000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1381000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1870000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1434000
CY2022Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3902000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2085000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
38801000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
37080000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
50317000
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
48867000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
175065000
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.25
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.24
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.33
CY2022Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.32
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.13
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.21
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.21
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.28
CY2022Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.27
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.96
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
88845000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
104031000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
103747000
CY2021Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
117130000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
413753000
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
43447000
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
38933000
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
38576000
CY2021Q4 us-gaap Costs And Expenses
CostsAndExpenses
60538000
CY2021 us-gaap Costs And Expenses
CostsAndExpenses
181494000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5040000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-10726000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5499000
CY2021Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-10337000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-31602000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
39926000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
39926000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
391303000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
391303000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
55845000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
55845000
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
41374000
CY2021Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
41374000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
528448000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
528448000
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.25
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.42
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.34
CY2021Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.25
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.26
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.25
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.39
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.34
CY2021Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.25
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.21

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
irwd-20221231_def.xml Edgar Link unprocessable
0001558370-23-001462-index-headers.html Edgar Link pending
0001558370-23-001462-index.html Edgar Link pending
0001558370-23-001462.txt Edgar Link pending
0001558370-23-001462-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
irwd-20221231.xsd Edgar Link pending
irwd-20221231x10k.htm Edgar Link pending
irwd-20221231x10k002.jpg Edgar Link pending
irwd-20221231xex10d8.htm Edgar Link pending
irwd-20221231xex23d1.htm Edgar Link pending
irwd-20221231xex31d1.htm Edgar Link pending
irwd-20221231xex31d2.htm Edgar Link pending
irwd-20221231xex32d1.htm Edgar Link pending
irwd-20221231xex32d2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R100.htm Edgar Link pending
R101.htm Edgar Link pending
R102.htm Edgar Link pending
R103.htm Edgar Link pending
R104.htm Edgar Link pending
R105.htm Edgar Link pending
R106.htm Edgar Link pending
R107.htm Edgar Link pending
R108.htm Edgar Link pending
R109.htm Edgar Link pending
R11.htm Edgar Link pending
R110.htm Edgar Link pending
R111.htm Edgar Link pending
R112.htm Edgar Link pending
R113.htm Edgar Link pending
R114.htm Edgar Link pending
R115.htm Edgar Link pending
R116.htm Edgar Link pending
R117.htm Edgar Link pending
R118.htm Edgar Link pending
R119.htm Edgar Link pending
R12.htm Edgar Link pending
R120.htm Edgar Link pending
R121.htm Edgar Link pending
R122.htm Edgar Link pending
R123.htm Edgar Link pending
R124.htm Edgar Link pending
R125.htm Edgar Link pending
R126.htm Edgar Link pending
R127.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
irwd-20221231_cal.xml Edgar Link unprocessable
irwd-20221231_lab.xml Edgar Link unprocessable
irwd-20221231_pre.xml Edgar Link unprocessable
irwd-20221231x10k_htm.xml Edgar Link completed
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R89.htm Edgar Link pending
R9.htm Edgar Link pending
R90.htm Edgar Link pending
R91.htm Edgar Link pending
R92.htm Edgar Link pending
R93.htm Edgar Link pending
R94.htm Edgar Link pending
R95.htm Edgar Link pending
R96.htm Edgar Link pending
R97.htm Edgar Link pending
R98.htm Edgar Link pending
R99.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending